{"id":926841,"date":"2026-01-13T09:06:44","date_gmt":"2026-01-13T14:06:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aons-latest-glp-1-research-reveals-long-term-employer-cost-savings-and-significant-reductions-in-cancer-risk-for-women\/"},"modified":"2026-01-13T09:06:44","modified_gmt":"2026-01-13T14:06:44","slug":"aons-latest-glp-1-research-reveals-long-term-employer-cost-savings-and-significant-reductions-in-cancer-risk-for-women","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aons-latest-glp-1-research-reveals-long-term-employer-cost-savings-and-significant-reductions-in-cancer-risk-for-women\/","title":{"rendered":"Aon’s Latest GLP-1 Research Reveals Long-Term Employer Cost Savings and Significant Reductions in Cancer Risk for Women"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n CHICAGO<\/span>, Jan. 13, 2026<\/span> \/PRNewswire\/ —\u00a0Aon plc<\/a> (NYSE: AON), a leading global professional services firm, today released updated findings<\/a> from its multi-year study of U.S. commercial health claims data, building on its GLP-1<\/span> research first released<\/a> in April 2025. Drawing on medical and pharmacy claims data from over 192,000 GLP-1<\/span> users, the study provides evidence of both financial and clinical benefits.<\/p>\n

Aon observed that sustained use of GLP\u20111 therapies can significantly reduce medical cost growth over the long term for employers and improve workforce health outcomes. Notably, female GLP-1<\/span> users experienced a 47 percent reduction in hospitalizations for major cardiovascular events, approximately 50 percent lower incidence of ovarian cancer and a 14 percent lower incidence of breast cancer compared to female non-users. These findings highlight the potential of GLP-1<\/span> therapies to reduce cancer risk for women, offering important implications for workforce health management, particularly in industries with substantial female participation and high chronic disease risk.<\/p>\n

“Conditions like obesity, diabetes and cancer are among the most pressing health challenges facing employees, their families and the organizations that support them,” said Lisa Stevens, chief administrative officer of Aon. “Our research demonstrates the power of GLP-1<\/span> therapies to transform health outcomes, with especially promising results for women \u2014 including substantial reductions in cancer and heart risks. This progress offers real hope for advancing population health and helping millions of people lead healthier, fuller lives.”<\/p>\n

\n Key Findings from Multi-Year GLP-1<\/span> Study
<\/b>Aon leveraged a proprietary methodology from its Cost Efficiency Measurement solution and the firm’s Health Risk Analyzer to evaluate an extensive dataset of medical and pharmacy claims from over 50 million commercial lives, including 192,000 prescribed\u00a0GLP-1<\/span>\u00a0users, from July 2022 to March 2025. Aon’s latest analysis reveals:<\/p>\n